Ocumetics Technology Corp. (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO) has provided a corporate and operational update highlighting progress across its clinical program, manufacturing, regulatory initiatives, and commercialization efforts. The company reported positive six-month results from its first-in-human (FIH) study, supporting advancement to Group Two clinical surgeries. A financing initiative has been launched to fund completion of the FIH study and accelerate commercialization.
The next-generation accommodating intraocular lens, termed the Ocumetics Lens, features a breakthrough design expected to improve manufacturability, surgical performance, and scalability. Manufacturing of this redesigned lens has commenced in Germany with partner Amiplant GmbH in preparation for planned Group Two surgeries, which remain on track for Q3 2026 in Mexico City under Principal Investigator Dr. Raphael Vasquez. All regulatory requirements necessary to proceed to Group Two have been successfully completed.
Since reporting initial FIH clinical results, Ocumetics has executed multiple strategic initiatives. Positive six-month data have supported progression to Group Two surgeries, and manufacturing of the redesigned lens has begun. Strategic discussions continue with four of the world's seven largest ophthalmic companies regarding future partnership and commercialization opportunities. Management has conducted over 50 one-on-one meetings with institutional investors, family offices, and strategic industry participants at recent investor conferences, reflecting growing recognition of the company's clinical progress.
Proceeds from the financing initiative are expected to fund completion of Group Two FIH surgeries in Mexico City, finalize manufacturing and quality verification of clinical lenses, complete sterilization and packaging, advance regulatory and quality assurance programs, and continue strategic partnership initiatives. The company has met with representatives from four of the seven largest ophthalmic companies, with several expressing interest in reviewing additional clinical data after Group Two surgeries. Follow-up discussions are tentatively scheduled for early Q4 2026 following one-month patient results.
Six-month follow-up data from Group One patients continue to demonstrate encouraging safety and performance outcomes. The surgical team reported successful implantation procedures and favorable post-operative outcomes. Anecdotally, one patient previously considered legally blind is now qualified to drive. These outcomes provided the foundation for advancing to Group Two.
The redesigned Ocumetics Lens incorporates significant advancements including enhanced accommodative performance, simplified one-piece architecture, improved manufacturing consistency, elimination of internal interface materials (no air, water, or oil), optimized surgical implantation characteristics, improved compatibility with the redesigned lens delivery system, and greater scalability for commercial manufacturing. The company intends to use this lens for upcoming Group Two surgeries.
Manufacturing activities include finalization of production, product verification, sterilization, packaging, and release of clinical inventory ahead of planned Q3 2026 surgeries. Upon completion, patient recruitment and surgical scheduling will commence. Management believes positive one-month results from Group Two patients will represent another meaningful value-creation milestone as the company advances toward larger clinical studies, regulatory submissions, and eventual commercialization.
